Sanofi India Gets Relief as GST Authority Drops Rs 23.73 Crore Excess ITC Notice
Mumbai: Sanofi India Limited has received an adjudication order from the Commercial Tax Officer (Audit)-6.1, DGSTO-6, Bengaluru, dropping a Goods and Services Tax (GST) show cause notice that had alleged excess availment of Input Tax Credit (ITC) amounting to Rs 23.73 crore for the financial year 2022-23.
In a regulatory filing, the pharmaceutical company informed the stock exchanges that the proceedings were concluded following the payment of Rs 17,680, comprising Rs 10,128 towards Central Goods and Services Tax (CGST) and State Goods and Services Tax (SGST), and Rs 7,552 as interest. The payment related to certain blocked credit items.
The matter originated from a show cause notice dated September 25, 2026, issued by the Commercial Tax Officer (Audit)-6.1, DGSTO-6, Bengaluru. The notice alleged that Sanofi India had availed excess Input Tax Credit during the period from April 2022 to March 2023 and proposed to determine a tax liability of Rs 23,73,76,507.
Following the notice, the company submitted its explanations and representations before the tax authorities. After considering the submissions, the Commercial Tax Officer issued an adjudication order dated November 16, 2026, under Section 73 of the Karnataka Goods and Services Tax Act, 2017.
As per the adjudication order, the proceedings were concluded upon payment of the applicable tax and interest amounting to Rs 17,680. The authority confirmed that no further amount was payable by the company and dropped the show cause notice.
Sanofi India further clarified that the order would have no material impact on its financial, operational or other activities.
Sanofi India Limited is part of the global Sanofi Group, a biopharmaceutical company focused on developing and delivering medicines and healthcare solutions across various therapeutic areas. Its operations in India include pharmaceutical products catering to multiple healthcare needs.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.